FDA asks Geron to Halt Development of Imetelstat The FDA has placed it’s only pipeline candidate, imetelstat, on full clinical hold. The news sent shares of GERN plunging 61% on March 12, 2014. Geron had submitted an Investigation New Drug (IND) application for imetelstat, but the FDA issued a verbal notice halting the trials. This […]
Synopsis of ASH 2013 Abstract – Peginvera study
by Dr. Angela Fleischman Synopsis of ASH 2013 Abstract: “Analysis of Molecular Responses and Chromosomal Aberrations in patients with PV treated with Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) in the Peginvera study” by Them et al This abstract describes the chromosomal analysis of PV patients on the Peginvera study (a study investigating a long-acting IFNa which can be […]
New Physician Based MPN Newsletter Emerges
MPN Updates – New Resource for Physicians by David Wallace As the number of MPN patients continues to grow, the need for innovative, physician-based resources has started to develop. While patient based (and Foundation/non-profit) websites focused on MPNs have flourished during the last few years, our disease tends to get tossed into the general “blood cancer” coverage, […]
Proposed Revision of WHO Diagnostic Criteria for MPNs
Synopsis of: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for Myeloproliferative Neoplasms by Dr. Angela Fleischman We are rapidly learning more about the mutations acquired by cancer cells, this is particularly evident in blood malignancies. Most recently, calreticulin mutations have been identified in the majority of […]
PV Reporter Newsletter #5, Feb. 8, 2014
PV Reporter Update Greetings PV Reporter readers – I want to give you an update on some recent activity as we weather the winter chill. This is an exciting time, as there are many discoveries being made in the MPN world. As you may have guessed by now, I don’t send out too many newsletters […]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 42
- Next Page »
